<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-161479" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dutasteride</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al-Horani</surname>
            <given-names>Rami A.</given-names>
          </name>
          <aff>Xavier University of Louisiana</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rami Al-Horani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-161479.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Dutasteride was approved by the US Food and Drug Administration (FDA) in 2001 and has also been used off-label for several conditions.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA approved dutasteride in 2001 for the management of symptomatic benign prostatic hyperplasia to alleviate symptoms and decrease the risk of acute urinary retention and the potential need for surgery.<xref ref-type="bibr" rid="article-161479.r1">[1]</xref>&#x000a0;Dutasteride is approved for this indication both as a monotherapy as well as a dual therapy with the alpha-blocker tamsulosin.<xref ref-type="bibr" rid="article-161479.r1">[1]</xref><xref ref-type="bibr" rid="article-161479.r2">[2]</xref><xref ref-type="bibr" rid="article-161479.r3">[3]</xref>&#x000a0;As per the American Urological Association (AUA 2021) guidelines, the use of 5&#x003b1;-reductase inhibitors (5-ARIs) like dutasteride, either alone or in combination with &#x003b1;-blockers, is strongly recommended for the management of benign prostatic hyperplasia/lower urinary tract symptoms. This suggestion aims to prevent the progression of benign prostatic hyperplasia and urinary tract symptoms, decrease the risks of urinary retention, and reduce the requirement for future prostate-related surgery.<xref ref-type="bibr" rid="article-161479.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Dutasteride is prescribed off-label for androgenic alopecia, also known as male pattern hair loss.<xref ref-type="bibr" rid="article-161479.r5">[5]</xref>&#x000a0;Although not approved by the FDA, randomized clinical trials yielded significant evidence in support of dutasteride efficacy in mild to moderate androgenetic alopecia in men.<xref ref-type="bibr" rid="article-161479.r6">[6]</xref><xref ref-type="bibr" rid="article-161479.r7">[7]</xref><xref ref-type="bibr" rid="article-161479.r8">[8]</xref><xref ref-type="bibr" rid="article-161479.r9">[9]</xref>&#x000a0;This was not only in comparison to placebo but also in comparison to finasteride. This 5&#x003b1;-reductase inhibitor has received official approval for use in patients with androgenic alopecia.<xref ref-type="bibr" rid="article-161479.r10">[10]</xref>&#x000a0;While off-label use requires careful consideration and adherence to evidence-based practices, dutasteride may provide a valuable alternative for managing this condition. Importantly, the use of dutasteride as prevention against prostate cancer in high-risk men was found to reduce the incidence of prostate cancer compared with a placebo.<xref ref-type="bibr" rid="article-161479.r11">[11]</xref><xref ref-type="bibr" rid="article-161479.r12">[12]</xref>&#x000a0;Although not adequately supported, literature reports other off-label uses in the treatment of excessive hair growth in women with hirsutism and as hormonal therapy in transgender individuals.<xref ref-type="bibr" rid="article-161479.r13">[13]</xref><xref ref-type="bibr" rid="article-161479.r14">[14]</xref><xref ref-type="bibr" rid="article-161479.r15">[15]</xref>&#x000a0;As per AUA guidelines, clinicians may consider 5&#x003b1;-reductase inhibitors such as dutasteride as a treatment option to minimize intraoperative bleeding and the perioperative requirement for blood transfusion following procedures like transurethral resection of the prostate (TURP) or other surgical interventions for BPH.<xref ref-type="bibr" rid="article-161479.r4">[4]</xref></p>
      </sec>
      <sec id="article-161479.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Mechanism</bold>
</p>
        <p>Dutasteride is an aza-steroid medication belonging to the class of 5&#x003b1;-reductase inhibitors. Dutasteride is classified as a potent, competitive, and irreversible mechanism-based inhibitor of types I and II of 5&#x003b1;-reductase. The enzyme 5&#x003b1;-reductase intracellularly converts testosterone to a more potent androgen known as dihydrotestosterone (DHT).<xref ref-type="bibr" rid="article-161479.r16">[16]</xref>&#x000a0;The type I 5&#x003b1;-reductase is primarily found in skin-related sebaceous glands, sweat glands, and keratinocytes and synthesizes about 33% of circulating DHT. The type II 5&#x003b1;-reductase isozyme is predominantly found in male genital tract-associated structures such as the epididymis, vas deferens, seminal vesicles, and prostate. Type II&#x000a0;is responsible for about 66% of circulating DHT.<xref ref-type="bibr" rid="article-161479.r17">[17]</xref><xref ref-type="bibr" rid="article-161479.r18">[18]</xref>&#x000a0;Given the dual inhibition of the&#x000a0;2 types of 5&#x003b1;-reductases, dutasteride causes a near-complete suppression of DHT. More than a 90% reduction of serum DHT levels is seen with dutasteride, whereas only a 70% reduction of serum DHT levels is caused by finasteride.<xref ref-type="bibr" rid="article-161479.r19">[19]</xref><xref ref-type="bibr" rid="article-161479.r20">[20]</xref></p>
        <p>By establishing a stable complex with 5&#x003b1;-reductase, dutasteride inhibits the conversion of testosterone to DHT, which exhibits a higher affinity to androgen receptors. By acting on those receptors, DHT modulates genes that dictate cell proliferation.<xref ref-type="bibr" rid="article-161479.r21">[21]</xref>&#x000a0;DHT seems to be the principal androgen responsible for the maturation of the prostate gland during development and its growth in later life through normal masculinization of the external genitalia.<xref ref-type="bibr" rid="article-161479.r22">[22]</xref>&#x000a0;Thus, reducing the serum DHT levels decreases prostatic volume and increases epithelial apoptosis. Accordingly, long-term use of dutasteride has been shown to reduce prostatic volume and provide relief of reduced urinary tract symptoms associated with an enlarged prostate. In addition, dutasteride has been established to decrease the frequency with which patients must undergo hyperplasia-related surgical procedures.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> After administration of a single dose of 0.5 mg dutasteride, the peak concentration (Tmax) was attained within 120 to 180 minutes.<xref ref-type="bibr" rid="article-161479.r23">[23]</xref>&#x000a0;Studies have shown that this Tmax increases significantly in patients who take the drug with food. Dutasteride takes approximately 3 to 6 months to reach a steady-state concentration.<xref ref-type="bibr" rid="article-161479.r24">[24]</xref>&#x000a0;Daily drug administration achieved 65% of steady-state concentration after 1 month and 90% after 3 months. Making patients aware of this estimation can help set realistic expectations in managing symptomatic BPH using dutasteride.<xref ref-type="bibr" rid="article-161479.r25">[25]</xref>&#x000a0;The oral bioavailability of 0.5 mg dutasteride formulation is approximately 60%.<xref ref-type="bibr" rid="article-161479.r24">[24]</xref><xref ref-type="bibr" rid="article-161479.r26">[26]</xref>&#x000a0;Although the maximum plasma level was found to be reduced by up to 15% when dutasteride was given with food, this effect is clinically irrelevant.</p>
        <p><bold>Distribution:</bold> Dutasteride exhibits a large volume of distribution between 300 L and 500 L, indicating that it is extensively distributed throughout the body, including in semen. After daily oral administration of 0.5 mg dutasteride in healthy subjects for 12 months, approximately 12% of serum dutasteride was partitioned into semen.<xref ref-type="bibr" rid="article-161479.r24">[24]</xref><xref ref-type="bibr" rid="article-161479.r27">[27]</xref>&#x000a0;Dutasteride is 99% bound to albumin and 96.6% bound to &#x003b1;1-acid glycoprotein in the serum, indicating extensive protein binding and potentially significant drug-drug interaction issues.</p>
        <p><bold>Metabolism:</bold> Dutasteride undergoes extensive hepatic metabolism mediated by CYP3A4/5. Several minor and major hydroxylated metabolites are formed. The activity of 6-&#x003b2;-hydroxy-dutasteride is comparable to that of dutasteride.<xref ref-type="bibr" rid="article-161479.r28">[28]</xref></p>
        <p><bold>Excretion:</bold> Less than 1% of the medication is eliminated renally. Approximately 45% of the medication is eliminated in feces (5% unchanged and 40% as metabolites).<xref ref-type="bibr" rid="article-161479.r23">[23]</xref>&#x000a0;The elimination half-life of dutasteride is up to 5 weeks, significantly longer than finasteride, which lasts 5 to 6 hours. Total body clearance is approximately 0.6 L/hour, indicating apparent linear clearance.<xref ref-type="bibr" rid="article-161479.r25">[25]</xref></p>
        <p>
<bold>Onset and Duration of Response</bold>
</p>
        <p>Significant symptom improvement is evident in patients receiving 0.5 mg daily after 3 to 12 months of treatment.<xref ref-type="bibr" rid="article-161479.r25">[25]</xref>&#x000a0;Substantial reductions in the prostate volume are apparent after 1 month and increases in maximum urine flow rate are evident after 3 months. With daily doses of 0.5 mg, median serum DHT levels fell by 85% and 90% after 1 and 2 weeks, respectively.</p>
      </sec>
      <sec id="article-161479.s3" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Available Dosage Forms and Strengths:</bold>&#x000a0;Dutasteride is administered as an oral capsule.<xref ref-type="bibr" rid="article-161479.r29">[29]</xref>&#x000a0;A fixed-dose combination of dutasteride/tamsulosin is available for the treatment of benign prostatic hyperplasia.&#x000a0;The regular strength used is 0.5 mg/capsule.</p>
        <p><bold>Adult Dosage:</bold>&#x000a0;For benign prostatic hyperplasia, dutasteride is used as monotherapy (0.5 mg oral once daily) or as a combination therapy with tamsulosin (0.5 mg dutasteride and 0.4 mg tamsulosin once daily).</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic Impairment:</bold>&#x000a0;No dosage adjustments are provided in the manufacturer's labeling. Dutasteride is extensively hepatically metabolized, and plasma concentration could be increased in hepatic impairment. Dutasteride has been associated with transient serum aminotransferase elevations in controlled trials, comparable to or lower than those observed with placebo therapy, and rarely necessitating dose modification.<xref ref-type="bibr" rid="article-161479.r30">[30]</xref></p>
        <p><bold>Renal Impairment:</bold>&#x000a0;No dutasteride dose adjustment is necessary in patients with renal impairment.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Given the mechanism of action and results of animal reproduction studies, in-utero exposure to dutasteride may cause fetal harm. Dutasteride has been shown to cause congenital disabilities in male children secondary to its inhibition of DHT.<xref ref-type="bibr" rid="article-161479.r31">[31]</xref>&#x000a0;Therefore, dutasteride is contraindicated during pregnancy. The medication should not be handled by patients who are or who may be pregnant. If contact with a broken capsule occurs, the exposed area must be immediately washed with water and soap because dutasteride can be absorbed through the skin.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Available evidence is not sufficient for determining infant risk when used during breastfeeding. Dutasteride's absence or presence in breast milk has not been demonstrated.<xref ref-type="bibr" rid="article-161479.r32">[32]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Dutasteride is not approved for use in pediatric patients, and its safety and effectiveness in this population have not been established.</p>
        <p><bold>Older&#x000a0;patients:</bold>&#x000a0;Dutasteride is safe for older adults. Patients older than 65 do not require dose adjustments based on the pharmacokinetic parameters of the 0.5 mg dosage form.</p>
        <p><bold>Male Patients:&#x000a0;</bold>Dutasteride has been shown to decrease semen volume, total sperm count, and sperm motility.<xref ref-type="bibr" rid="article-161479.r33">[33]</xref>&#x000a0;The effects on total sperm count were irreversible after 24 weeks of follow-up. The effects on fertility remain unknown.</p>
      </sec>
      <sec id="article-161479.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>Some patients taking dutasteride may experience sexual dysfunction, which can manifest as impotence (0.3% to 12%), decreased libido (up to 4.5%), or difficulty ejaculating (up to 7.8%).<xref ref-type="bibr" rid="article-161479.r20">[20]</xref><xref ref-type="bibr" rid="article-161479.r34">[34]</xref><xref ref-type="bibr" rid="article-161479.r35">[35]</xref>&#x000a0;These sexual adverse effects may persist despite discontinuing dutasteride. Furthermore, some patients have reported experiencing acute urinary retention while using dutasteride.<xref ref-type="bibr" rid="article-161479.r36">[36]</xref>&#x000a0;</p>
        <p>The impact of dutasteride on fertility has not been widely studied, but preliminary results indicate that mild reductions in semen parameters may be present while taking the medication.<xref ref-type="bibr" rid="article-161479.r37">[37]</xref></p>
        <p>One adverse effect less commonly associated with dutasteride is gynecomastia (&#x02264;1%), a condition characterized by the development of breast tissue in male patients.<xref ref-type="bibr" rid="article-161479.r38">[38]</xref><xref ref-type="bibr" rid="article-161479.r34">[34]</xref>&#x000a0;This results from the inhibition of testosterone's conversion to DHT and the subsequent increase in the peripheral conversion of testosterone to estrogen.<xref ref-type="bibr" rid="article-161479.r19">[19]</xref>&#x000a0;Increased estrogen is known to cause increased accumulation of breast tissue in male patients.<xref ref-type="bibr" rid="article-161479.r39">[39]</xref>&#x000a0;Patients should be informed of the potential risk of gynecomastia before initiating dutasteride treatment.</p>
        <p>Depression and its persistence following discontinuation is an established adverse effect of finasteride, the other &#x003b1;-reductase inhibitor.<xref ref-type="bibr" rid="article-161479.r40">[40]</xref>&#x000a0;While there is comparatively less evidence linking dutasteride to depression, it is recommended to monitor patients for mood changes or signs of suicidal ideation while taking dutasteride. However, the link between dutasteride and depression remains under investigation.<xref ref-type="bibr" rid="article-161479.r41">[41]</xref></p>
        <p>Less frequently, dutasteride has been associated with dizziness, headaches, and gastrointestinal upset.<xref ref-type="bibr" rid="article-161479.r19">[19]</xref>&#x000a0;Rare but serious adverse events include angioedema, cutaneous hypersensitivity, and prostate cancer.&#x000a0;</p>
        <p>
<bold>Test Interactions</bold>
</p>
        <p>Prostate-specific antigen (PSA) levels drop in treated patients. After about 3 months of treatment, PSA levels stabilize to a baseline of approximately 50% of the pre-treatment value.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Dutasteride is not significantly affected by the coadministration with &#x003b1;-blockers (eg, terazosin, doxazosin, tamsulosin).<xref ref-type="bibr" rid="article-161479.r24">[24]</xref>&#x000a0;Alpha-blockers are often used in conjunction with dutasteride to manage benign prostatic hyperplasia.</p>
        <p>However, other drug-drug interactions may exist, although they may vary in severity. Concurrent use of dutasteride and itraconazole may result in increased dutasteride exposure and an increased risk of dutasteride-related adverse effects. Furthermore, simultaneous administration of ceritinib (strong CYP3A inhibitor) and CYP3A substrates in dutasteride may increase CYP3A substrate exposure. Concurrent use of dutasteride and fluconazole may also result in increased dutasteride exposure and risk for toxicity.</p>
        <p>Although the severity is moderate, it is essential to know that concurrent use of dutasteride and ciprofloxacin, ketoconazole, verapamil, diltiazem, ritonavir, or cimetidine may increase dutasteride plasma concentrations.<xref ref-type="bibr" rid="article-161479.r42">[42]</xref></p>
        <p>
<bold>Drug-Food Interactions</bold>
</p>
        <p>Maximum serum concentrations of dutasteride are decreased by 10% to 15% when taken with food, which is not clinically significant. Thus, the medication is to be taken without regard to meals.</p>
      </sec>
      <sec id="article-161479.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Use of dutasteride during pregnancy or in women who may become pregnant is contraindicated. Likewise, use in children is contraindicated.<xref ref-type="bibr" rid="article-161479.r24">[24]</xref>&#x000a0;Dutasteride is contraindicated in patients with clinically significant hypersensitivity to dutasteride, excipients,&#x000a0;or finasteride.<xref ref-type="bibr" rid="article-161479.r43">[43]</xref></p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>No boxed warnings have been reported at the time of writing this article.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>As a precaution, donating blood during or for&#x000a0;6 months following treatment cessation should be avoided due to the risk of administration to a transfusion recipient who is pregnant. Dutasteride may cause fetal harm. Therefore, capsules should not be handled by pregnant patients or those of childbearing potential due to the potential risk of fetal exposure and potential risk to a male fetus from cutaneous absorption. If contact occurs, the area should be immediately washed with soap and water.</p>
        <p>Dutasteride undergoes extensive metabolism by the hepatic cytochrome P450 enzyme system. Inhibition of this metabolism can significantly increase the concentration of the drug, possibly increasing the risk of adverse effects. As a result, dutasteride should be avoided in patients with severe liver disease, while it should be used with caution in patients with milder hepatic impairment.<xref ref-type="bibr" rid="article-161479.r30">[30]</xref></p>
        <p>The medication has been reported to affect male fertility, as mentioned above.<xref ref-type="bibr" rid="article-161479.r33">[33]</xref></p>
        <p>Clinicians should monitor PSA levels periodically to monitor the response to therapy. The increase in PSA levels may indicate prostate cancer.<xref ref-type="bibr" rid="article-161479.r44">[44]</xref>&#x000a0;Lastly, other urological conditions that may cause similar symptoms of BPH should be considered before initiation.</p>
      </sec>
      <sec id="article-161479.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The exact therapeutic index of dutasteride is not well-defined, and patients taking it should be made aware of the associated adverse effects.<xref ref-type="bibr" rid="article-161479.r24">[24]</xref>&#x000a0;Patients should report any breast enlargement or tenderness as well as any sexual side effects.<bold>&#x000a0;</bold>Patients should be counseled on the fact that these sexual side effects may persist after discontinuation of dutasteride.<xref ref-type="bibr" rid="article-161479.r34">[34]</xref><xref ref-type="bibr" rid="article-161479.r40">[40]</xref></p>
        <p>Clinicians should monitor patients for signs of an allergic reaction to dutasteride, including itching, skin rash, lips, tongue, or face swelling. Patients should stop taking dutasteride and inform their healthcare team if any of these symptoms present.&#x000a0;</p>
        <p>Prostate cancer and urological diseases should be ruled out before initiating therapy and periodically. As mentioned earlier, PSA is expected to decrease by approximately 50% following 3 to 6 months of treatment. Therefore, a new baseline should be established to evaluate potential cancer-related changes to PSA. The American Urological Association Symptom Index (AUA-SI)/International Prostate Symptom Score (IPSS) should be used to assess the severity of benign prostatic hyperplasia.<xref ref-type="bibr" rid="article-161479.r4">[4]</xref>&#x000a0;Improvement in the signs and symptoms of benign prostatic hyperplasia, such as increased urinary flow, indicates efficacy.</p>
      </sec>
      <sec id="article-161479.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Single doses of 0.5 mg dutasteride for the management of benign prostatic hyperplasia or androgenic alopecia have exhibited a favorable safety profile with minimal significant adverse events.<xref ref-type="bibr" rid="article-161479.r24">[24]</xref>&#x000a0;There are no reports of toxicity following acute overdose. In studies, single doses of up to 40 mg (80 times the standard therapeutic dose) for&#x000a0;7 days have been administered with no significant effects reported.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>While dutasteride overdose cases are rare, it is essential to acknowledge the potential for adverse drug reactions. In the absence of a well-established antidote for dutasteride overdose, treatment of overdose is symptomatic and supportive. Given the large volume of distribution and high protein binding, dialysis is unlikely to be beneficial. Medical attention should be sought immediately if an overdose is suspected. Allergic reactions can be treated with antihistamines with or without inhaled &#x003b2;-agonists and corticosteroids.<xref ref-type="bibr" rid="article-161479.r45">[45]</xref>&#x000a0;Treating severe anaphylaxis involves oxygen supplementation, airway management, epinephrine, IV fluids, and EKG monitoring. Further research may provide additional insights into the management of potential overdose.</p>
      </sec>
      <sec id="article-161479.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Benign prostatic hyperplasia (BPH) is a condition linked with lower urinary tract symptoms (LUTS), and it is becoming more prevalent among the aging population. Over the last 20 years, the morbidity related to BPH and BPH-associated LUTS has surged by a substantial 80%, underscoring the escalating significance of this condition.<xref ref-type="bibr" rid="article-161479.r46">[46]</xref>&#x000a0;UTS not only significantly impacts patient quality of life but also exhibits more pronounced effects on depression and anxiety compared to other chronic illnesses such as gout, diabetes, and hypertension.<xref ref-type="bibr" rid="article-161479.r47">[47]</xref><xref ref-type="bibr" rid="article-161479.r48">[48]</xref><xref ref-type="bibr" rid="article-161479.r49">[49]</xref>&#x000a0;Effectively managing BPH, especially when accompanied by LUTS, is crucial to address these challenges.</p>
        <p>Clinically effective options for the management of symptomatic BPH include dutasteride and other 5&#x003b1;-reductase inhibitors. The suitability of dutasteride as a management choice depends on individual patient needs, health status, and ability to obtain and adhere to the prescribed medication. The multifaceted nature of patient quality of life in the context of BPH encompasses various factors, including education level, overall health, presence of chronic diseases, income, alcohol consumption, and physical activity.<xref ref-type="bibr" rid="article-161479.r50">[50]</xref>&#x000a0;Therefore, a comprehensive approach to BPH management is essential for success, requiring the collaboration of an interprofessional healthcare team. To assess a patient's eligibility for dutasteride therapy and ensure seamless integration with a comprehensive BPH management plan, clinicians (MDs, DOs, NPs, PAs), nurses, urologists, case workers, and pharmacists. The involvement of collaborative interprofessional teams holds significant potential for enhancing patient outcomes, minimizing adverse effects associated with BPH management, and delivering optimal patient care.</p>
      </sec>
      <sec id="article-161479.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=161479&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=161479">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/161479/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=161479">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-161479.s10">
        <title>References</title>
        <ref id="article-161479.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hoefner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>G</given-names>
              </name>
              <collab>ARIA3001 ARIA3002 and ARIA3003 Study Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.</article-title>
            <source>Urology</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>434</fpage>
            <page-range>434-41</page-range>
            <pub-id pub-id-type="pmid">12350480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimitropoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gravas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.</article-title>
            <source>Ther Adv Urol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-28</page-range>
            <pub-id pub-id-type="pmid">26834837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Oyarzabal Perez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roos</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Calomfirescu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brotherton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Vasylyev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manyak</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(&#x000ae;) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-na&#x000ef;ve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.</article-title>
            <source>BJU Int</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>450</fpage>
            <page-range>450-9</page-range>
            <pub-id pub-id-type="pmid">25565364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lerner</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>McVary</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bixler</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Stoffel</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Welliver</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management.</article-title>
            <source>J Urol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>206</volume>
            <issue>4</issue>
            <fpage>806</fpage>
            <page-range>806-817</page-range>
            <pub-id pub-id-type="pmid">34384237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Courtney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Triwongwarant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chim</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eisman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2023</year>
            <season>Sep-Dec</season>
            <volume>24</volume>
            <issue>18</issue>
            <fpage>1919</fpage>
            <page-range>1919-1922</page-range>
            <pub-id pub-id-type="pmid">37942878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eun</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Yeon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-8</page-range>
            <pub-id pub-id-type="pmid">20605255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Hordinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whiting</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stough</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rittmaster</surname>
                <given-names>RS</given-names>
              </name>
              <collab>Dutasteride Alopecia Research Team</collab>
            </person-group>
            <article-title>The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>1014</fpage>
            <page-range>1014-23</page-range>
            <pub-id pub-id-type="pmid">17110217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escamilla-Cruz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maga&#x000f1;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Escand&#x000f3;n-Perez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bello-Chavolla</surname>
                <given-names>OY</given-names>
              </name>
            </person-group>
            <article-title>Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>1721</fpage>
            <page-range>1721-1731</page-range>
            <pub-id pub-id-type="pmid">37432644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajoria</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rohit</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Tibrewal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>e42768</fpage>
            <pub-id pub-id-type="pmid">37663989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Yeon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Youn</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Effect of dutasteride 0.5&#x000a0;mg/d in men with androgenetic alopecia recalcitrant to finasteride.</article-title>
            <source>Int J Dermatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>1351</fpage>
            <page-range>1351-7</page-range>
            <pub-id pub-id-type="pmid">24898559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bostwick</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Brawley</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Gomella</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Marberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pettaway</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Teloken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Somerville</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Rittmaster</surname>
                <given-names>RS</given-names>
              </name>
              <collab>REDUCE Study Group</collab>
            </person-group>
            <article-title>Effect of dutasteride on the risk of prostate cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Apr</month>
            <day>01</day>
            <volume>362</volume>
            <issue>13</issue>
            <fpage>1192</fpage>
            <page-range>1192-202</page-range>
            <pub-id pub-id-type="pmid">20357281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grubb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Somerville</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manyak</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>189</volume>
            <issue>3</issue>
            <fpage>871</fpage>
            <page-range>871-7</page-range>
            <pub-id pub-id-type="pmid">23021996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ehrmann</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pugeat</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rosenfield</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>1233</fpage>
            <page-range>1233-1257</page-range>
            <pub-id pub-id-type="pmid">29522147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wesp</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons.</article-title>
            <source>Psychiatr Clin North Am</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-111</page-range>
            <pub-id pub-id-type="pmid">28159148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalayjian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laszlo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fassler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schonrock</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Delarose</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cirrincione</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2&#x000a0;years of hormone therapy.</article-title>
            <source>J Am Pharm Assoc (2003)</source>
            <year>2024</year>
            <season>Jan-Feb</season>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>283</fpage>
            <page-range>283-289.e2</page-range>
            <pub-id pub-id-type="pmid">37839699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Dutasteride: a review of its use in the management of prostate disorders.</article-title>
            <source>Drugs</source>
            <year>2008</year>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-85</page-range>
            <pub-id pub-id-type="pmid">18318566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thigpen</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Guileyardo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>McConnell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.</article-title>
            <source>J Clin Invest</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>903</fpage>
            <page-range>903-10</page-range>
            <pub-id pub-id-type="pmid">7688765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>NZ</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <article-title>Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.</article-title>
            <source>Asian J Androl</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>274</fpage>
            <page-range>274-9</page-range>
            <pub-id pub-id-type="pmid">24457841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marihart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Djavan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.</article-title>
            <source>Rev Urol</source>
            <year>2005</year>
            <season>Fall</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>203</fpage>
            <page-range>203-10</page-range>
            <pub-id pub-id-type="pmid">16985831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Fenter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gittleman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrill</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolford</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.</article-title>
            <source>Urology</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>709</fpage>
            <page-range>709-15</page-range>
            <pub-id pub-id-type="pmid">15072886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rittmaster</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The role of dihydrotestosterone in benign prostatic hyperplasia.</article-title>
            <source>Urology</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4 Suppl 1</issue>
            <fpage>2</fpage>
            <page-range>2-7</page-range>
            <pub-id pub-id-type="pmid">12657354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.</article-title>
            <source>Core Evid</source>
            <year>2005</year>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-56</page-range>
            <pub-id pub-id-type="pmid">22500150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villapalos-Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zubiaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Navares-G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saiz-Rodr&#x000ed;guez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a-Abril</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-V&#x000ed;lchez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rom&#x000e1;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abad-Santos</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>718281</fpage>
            <pub-id pub-id-type="pmid">34690761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Dutasteride.</article-title>
            <source>Drugs Aging</source>
            <year>2003</year>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>905</fpage>
            <page-range>905-16; discussion 917-8</page-range>
            <pub-id pub-id-type="pmid">14565784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gisleskog</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hammarlund-Udenaes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-8</page-range>
            <pub-id pub-id-type="pmid">10073740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pa&#x0015b;ko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodacki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Domaga&#x00142;a-Rodacka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Owczarek</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>83</volume>
            <fpage>1141</fpage>
            <page-range>1141-1145</page-range>
            <pub-id pub-id-type="pmid">27551761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tarter</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.</article-title>
            <source>Clin Interv Aging</source>
            <year>2009</year>
            <volume>4</volume>
            <fpage>251</fpage>
            <page-range>251-8</page-range>
            <pub-id pub-id-type="pmid">19554096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.</article-title>
            <source>Eur Urol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-8</page-range>
            <pub-id pub-id-type="pmid">12814679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fossler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McAleese</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Manyak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.</article-title>
            <source>Clin Drug Investig</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>763</fpage>
            <page-range>763-767</page-range>
            <pub-id pub-id-type="pmid">27356530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <chapter-title>Dutasteride</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>9</day>
            <pub-id pub-id-type="pmid">31643389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Morrill</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2004</year>
            <month>May</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>2179</fpage>
            <page-range>2179-84</page-range>
            <pub-id pub-id-type="pmid">15126539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koh</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Oon</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>New changes in pregnancy and lactation labelling: Review of dermatologic drugs.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>216</fpage>
            <page-range>216-226</page-range>
            <pub-id pub-id-type="pmid">31700976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drobnis</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Nangia</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>5&#x003b1;-Reductase Inhibitors (5ARIs) and Male Reproduction.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>1034</volume>
            <fpage>59</fpage>
            <page-range>59-61</page-range>
            <pub-id pub-id-type="pmid">29256127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rastrelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maseroli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Balercia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sforza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Forti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mannucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maggi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Inhibitors of 5&#x003b1;-reductase-related side effects in patients seeking medical care for sexual dysfunction.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>915</fpage>
            <page-range>915-20</page-range>
            <pub-id pub-id-type="pmid">22777612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traish</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guay</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Zitzmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Adverse side effects of 5&#x003b1;-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.</article-title>
            <source>J Sex Med</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>872</fpage>
            <page-range>872-84</page-range>
            <pub-id pub-id-type="pmid">21176115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Debruyne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Erps</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>C</given-names>
              </name>
              <collab>ARIA3001, ARIA3002 and ARIB3003 Study Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.</article-title>
            <source>Eur Urol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-94; discussion 495</page-range>
            <pub-id pub-id-type="pmid">15363566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amory</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Swerdloff</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bremner</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Haberer</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2007</year>
            <month>May</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>1659</fpage>
            <page-range>1659-65</page-range>
            <pub-id pub-id-type="pmid">17299062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schulman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pommerville</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000f6;fner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wachs</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.</article-title>
            <source>BJU Int</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>97</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-9; discussion 79-80</page-range>
            <pub-id pub-id-type="pmid">16336332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Swerdloff</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>JCM</given-names>
              </name>
            </person-group>
            <chapter-title>Gynecomastia: Etiology, Diagnosis, and Treatment</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">25905330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irwig</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>73</volume>
            <issue>9</issue>
            <fpage>1220</fpage>
            <page-range>1220-3</page-range>
            <pub-id pub-id-type="pmid">22939118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Argibay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiyoshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Association of 5&#x003b1;-Reductase Inhibitors With Dementia, Depression, and Suicide.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e2248135</fpage>
            <pub-id pub-id-type="pmid">36547981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>658</fpage>
            <pub-id pub-id-type="pmid">32457631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals.</article-title>
            <source>Hosp Pharm</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>595</fpage>
            <page-range>595-602</page-range>
            <pub-id pub-id-type="pmid">24421525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f6;rnebo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nordstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Discacciati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palsdottir</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;nberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lantz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Association of 5&#x003b1;-Reductase Inhibitors With Prostate Cancer Mortality.</article-title>
            <source>JAMA Oncol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>1019</fpage>
            <page-range>1019-1026</page-range>
            <pub-id pub-id-type="pmid">35587340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pflipsen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vega Colon</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis: Recognition and Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2020</year>
            <month>Sep</month>
            <day>15</day>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>355</fpage>
            <page-range>355-362</page-range>
            <pub-id pub-id-type="pmid">32931210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Launer</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>McVary</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Ricke</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>The rising worldwide impact of benign prostatic hyperplasia.</article-title>
            <source>BJU Int</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>127</volume>
            <issue>6</issue>
            <fpage>722</fpage>
            <page-range>722-728</page-range>
            <pub-id pub-id-type="pmid">33124118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.</article-title>
            <source>Urology</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-50</page-range>
            <pub-id pub-id-type="pmid">11834396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coyne</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Aiyer</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS.</article-title>
            <source>BJU Int</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>103 Suppl 3</volume>
            <fpage>4</fpage>
            <page-range>4-11</page-range>
            <pub-id pub-id-type="pmid">19302497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).</article-title>
            <source>Eur Urol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>824</fpage>
            <page-range>824-37</page-range>
            <pub-id pub-id-type="pmid">15925080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-161479.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009-2016.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Sep</month>
            <day>09</day>
            <volume>101</volume>
            <issue>36</issue>
            <fpage>e30091</fpage>
            <pub-id pub-id-type="pmid">36086750</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
